Alercell Inc has introduced a molecular leukemia diagnostic platform. The LENA Molecular Dx Leukemia Platform is a core group of 12 molecular diagnostic tests specialized in leukemia early diagnostic, treatment guidance, and MRD (Minimal residual disease) monitoring. All the tests are next generation DNA sequencing tests but can be processed on a standard qPCR machine, bringing easy access to a lot of data efficiently and quickly to bring a better outcome to patients.

Several of the tests are for research use only (RUO), such as the RUO LENA Q51 introduced by Alercell in January 2023. LENA Q51 is the most comprehensive test and covers all the other tests, but the company wanted to give access to all tests through the creation of the platform. The Alercell R&D team is constantly working to add new tests to cover all aspects of leukemia testing to provide practitioners with every single test available in one place.

Alercell has a goal of making sure that all its LENA leukemia tests are offered at very competitive pricing. Company leadership shares a strong belief that giving many patients, hospitals, and cancer centers access to quality testing at a lower price will increase the quantity of patients tested, thus permitting early detection and fast treatment of leukemia. Practitioners should make treatment decisions based on medical data, not on costs or insurance consideration.

The LENA leukemia tests have an easy-to-use protocol and can be run on standard qPCR equipment. They are designed to handle the workflow in a clinical microbiology lab environment. The tests employ industry standard PCR and DNA purification technology.

“This new platform was designed to create a one-stop shop for leukemia, where practitioners do not need to look for many different manufacturers,” says Alercell Chairman and CEO Frederic Scheer. “Our goal at Alercell is to become the reference for leukemia and offer a complete solution. Early detection drastically enhances the survival rates of patients and Alercell is focusing on making sure that we give every patient the best chances of survival.”